Hansa Biopharma (Sweden) Insiders
| HNSA Stock | SEK 33.22 1.56 4.93% |
Hansa Biopharma employs about 150 people. The company is managed by 10 executives with a total tenure of roughly 21 years, averaging almost 2.0 years of service per executive, having 15.0 employees per reported executive. Breaking down Hansa Biopharma's management performance can provide insight into the firm performance.
| Henk Troostwijk President Vice President Commercial Operations |
| Christian Kjellman President Senior Vice President Research and Development |
Hansa |
Hansa Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2718) % which means that it has lost $0.2718 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8941) %, meaning that it generated substantial loss on money invested by shareholders. Hansa Biopharma's management efficiency ratios could be used to measure how well Hansa Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Hansa Biopharma Workforce Comparison
Hansa Biopharma AB is rated # 2 in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 500. Hansa Biopharma totals roughly 150 in number of employees claiming about 30% of stocks in Biotechnology industry.
Hansa Biopharma AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Hansa Biopharma AB Price Series Summation is a cross summation of Hansa Biopharma price series and its benchmark/peer.
Hansa Biopharma Notable Stakeholders
A Hansa Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Hansa Biopharma often face trade-offs trying to please all of them. Hansa Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Hansa Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Henk Troostwijk | Vice President Commercial Operations | Profile | |
| Christian Kjellman | Senior Vice President Research and Development | Profile | |
| Lena Winstedt | Vice President Project Management | Profile | |
| EvaMaria Joed | Vice President Finance & Administration | Profile | |
| Donato Spota | CFO VP | Profile | |
| Klaus Sindahl | Head Relations | Profile | |
| Sren MSc | Pres CEO | Profile | |
| Katja Margell | Head Communications | Profile | |
| Anne Lanner | VP Officer | Profile | |
| Emanuel Bjrne | VP Devel | Profile |
About Hansa Biopharma Management Performance
The success or failure of an entity such as Hansa Biopharma AB often depends on how effective the management is. Hansa Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Hansa management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Hansa management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 60 people.
Please note, the imprecision that can be found in Hansa Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Hansa Biopharma AB. Check Hansa Biopharma's Beneish M Score to see the likelihood of Hansa Biopharma's management manipulating its earnings.
Hansa Biopharma Workforce Analysis
Traditionally, organizations such as Hansa Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Hansa Biopharma within its industry.Hansa Biopharma Manpower Efficiency
Return on Hansa Biopharma Manpower
| Revenue Per Employee | 1M | |
| Revenue Per Executive | 15.5M | |
| Net Loss Per Employee | 4.1M | |
| Net Loss Per Executive | 61M |
Additional Tools for Hansa Stock Analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.